European Patent Office Upholds Introgen Patent

Law360, New York (November 13, 2003, 12:00 AM EST) -- Introgen Therapeutics Inc. said its patent on p53 therapy was upheld by the European Patent Office after being challenged by Schering-Plough Corp.

Earlier this year, Schering-Plough filed an opposition against the issuance of the European patent directed to "combination therapy with p53 and conventional chemotherapy and/or radiation."

This is the third successful outcome over a period of three years in oppositions involving Schering-Plough, Introgen said in a statement.

The patent, exclusively licensed to Introgen from The Board of Regents of The University of Texas System, covers...
To view the full article, register now.